Thymosin peptides / working resource
Primary source desk
Keep the original documents and the limits of their conclusions within reach.
Start with the product-specific question
Thymosin alpha-1 versus beta-4
Identify thymosin alpha-1, beta-4 and TB-500 before discussing outcomes. What should I know about thymosin alpha-1 versus beta-4?
Open the Thymosin library ↗TESTS randomized 1106 adults with sepsis across 22 centers in China;1089 were included in its modified intention-to-treat analysis.
Read the original record ↗
The original record comes first.
These are starting points for the Thymosin library. Read the source's exact question, product, population and date. A source can be authoritative for one claim and irrelevant to another.
Keep claims and sources together.
TESTS randomized 1106 adults with sepsis across 22 centers in China;1089 were included in its modified intention-to-treat analysis.
Supporting record ↗TESTS reported 28-day mortality of23.4% with thymosin alpha1 versus24.1% with placebo. The published correction gives a hazard ratio of0.97 (95%CI0.76-1.24), without a clear mortality benefit.
Supporting record ↗TESTS found no clear evidence of lower 28-day mortality and no statistically significant difference in secondary or safety outcomes.
Supporting record ↗The smaller Resetalpha supplement report described 120 completers and improved SOFA scores with thymosinalpha 1 added to standard care.
Supporting record ↗These fields stay in this page until you leave or reload. No notes are saved or transmitted. Print a copy if you want to keep your work. Educational organization tools do not replace clinical advice.